|
1
|
Bini A, Brandolini J, Cassanelli N, Davoli
F, Dolci G, Sellitri F and Stella F: Typical and atypical pulmonary
carcinoids: Our institutional experience. Interact Cardiovasc
Thorac Surg. 7:415–418. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grozinsky-Glasberg S and Pavel M:
Inhibition of mTOR in carcinoid tumors. Target Oncol. 7:189–195.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Travis WD, Rush W, Flieder DB, Falk R,
Fleming MV, Gal AA and Koss MN: Survival analysis of 200 pulmonary
neuroendocrine tumors with clarification of criteria for atypical
carcinoid and its separation from typical carcinoid. Am J Surg
Pathol. 22:934–944. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cardillo G, Sera F, Di Martino M, Graziano
P, Giunti R, Carbone L, Facciolo F and Martelli M: Bronchial
carcinoid tumors: Nodal status and long-term survival after
resection. Ann Thorac Surg. 77:1781–1785. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rugge M, Fassan M, Clemente R, Rizzardi G,
Giacomelli L, Pennelli G, Mescoli C, Segat D and Rea F:
Bronchopulmonary carcinoid: Phenotype and long-term outcome in a
single-institution series of italian patients. Clin Cancer Res.
14:149–154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thomas CF Jr, Tazelaar HD and Jett JR:
Typical and atypical pulmonary carcinoids: Outcome in patients
presenting with regional lymph node involvement. Chest.
119:1143–1150. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chakravarthy A and Abrams RA: Radiation
therapy in the management of patients with malignant carcinoid
tumors. Cancer. 75:1386–1390. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jodrell DI and Smith IE: Carboplatin in
the treatment of metastatic carcinoid tumours and paraganglioma: A
phase ii study. Cancer Chemother Pharmacol. 26:62–64. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Saltz L, Lauwers G, Wiseberg J and Kelsen
D: A phase II trial of carboplatin in patients with advanced APUD
tumors. Cancer. 72:619–622. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Leotlela PD, Jauch A, Holgreve-Grez A and
Thakker RV: Genetics of neuroendocrine and carcinoid tumours.
Endocr Relat Cancer. 10:437–450. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Forde PM, Hooker CM, Boikos SA, Petrini I,
Giaccone G, Rudin CM, Yang SC, Illei PB, Hann CL, Ettinger DS, et
al: Systmic therapy, clinical outcomes, and overall survival in
locally advanced or metastatic pulmonary carcinoid: A brief report.
J Thorac Oncol. 9:414–418. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rickman OB, Vohra PK, Sanyal B, Vrana JA,
Aubry MC, Wigle DA and Thomas CF Jr: Analysis of erbb receptors in
pulmonary carcinoid tumors. Clin Cancer Res. 15:3315–3324. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Campbell MR, Amin D and Moasser MM: Her3
comes of age: New insights into its functions and role in
signaling, tumor biology, and cancer therapy. Clin Cancer Res.
16:1373–1383. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lemmon MA and Schlessinger J: Cell
signaling by receptor tyrosine kinases. Cell. 141:1117–1134. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roskoski R Jr: ErbB/HER protein-tyrosine
kinases: Structures and small molecule inhibitors. Pharmacol Res.
87:42–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kol A, van Terwisscha Scheltinga AG,
Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EG and Schröder
CP: HER3, serious partner in crime: Therapeutic approaches and
potential biomarkers for effect of HER3-targeting. Pharmacol Ther.
143:1–11. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Roskoski R Jr: The ErbB/her family of
protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Travis WD, Brambila E, Müller-Hermelink HK
and Harris CC: World Health Organization Classification of Tumours.
Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and
Heart. IARC Press. (Lyon). 2004.
|
|
19
|
Lattanzio R, Marchisio M, La Sorda R,
Tinari N, Falasca M, Alberti S, Miscia S, Ercolani C, Di Benedetto
A, Perracchio L, et al: Overexpression of activated phospholipase
Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast
cancer patients undergoing adjuvant chemotherapy. Int J Cancer.
132:1022–1031. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Veschi S, Lattanzio R, Aceto GM, Curia MC,
Magnasco S, Angelucci D, Cama A, Piantelli M and Battista P:
Alterations of MEN1 and E-cadherin/β-catenin complex in sporadic
pulmonary carcinoids. Int J Oncol. 41:1221–1228. 2012.PubMed/NCBI
|
|
21
|
Battista P, Pizzicannella G, Vitullo P,
Palmirotta R and Mariani-Costantini R: The epidermal growth factor
family in pulmonary carcinoids: Immunohistochemical evidence of
growth-promoting circuits. Mod Pathol. 6:162–166. 1993.PubMed/NCBI
|
|
22
|
Rusch VW, Klimstra DS and Venkatraman ES:
Molecular markers help characterize neuroendocrine lung tumors. Ann
Thorac Surg. 62:798–810. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wilkinson N, Hasleton PS, Wilkes S and
Quigley A: Lack of C-erbB-2 protein expression in pulmonary
carcinoid tumours. J Clin Pathol. 44:3431991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amin DN, Campbell MR and Moasser MM: The
role of HER3, the unpretentious member of the HER family, in cancer
biology and cancer therapeutics. Semin Cell Dev Biol. 21:944–950.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ueno Y, Sakurai H, Tsunoda S, Choo MK,
Matsuo M, Koizumi K and Saiki I: Heregulin-induced activation of
ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and
metastasis in melanoma cells. Int J Cancer. 123:340–347. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sundvall M, Iljin K, Kilpinen S, Sara H,
Kallioniemi OP and Elenius K: Role of ErbB4 in breast cancer. J
Mammary Gland Biol Neoplasia. 13:259–268. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Starr A, Greif J, Vexler A,
Ashkenazy-Voghera M, Gladesh V, Rubin C, Kerber G, Marmor S,
Lev-Ari S, Inbar M, et al: ErbB4 increases the proliferation
potential of human lung cancer cells and its blockage can be used
as a target for anti-cancer therapy. Int J Cancer. 119:269–274.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Swarts DR, Scarpa A, Corbo V, Van
Criekinge W, van Engeland M, Gatti G, Henfling ME, Papotti M,
Perren A, Ramaekers FC, et al: Men1 gene mutation and reduced
expression are associated with poor prognosis in pulmonary
carcinoids. J Clin Endocrinol Metab. 99:E374–E378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Swarts DR, Claessen SM, Jonkers YM, van
Suylen RJ, Dingemans AM, de Herder WW, de Krijger RR, Smit EF,
Thunnissen FB, Seldenrijk CA, et al: Deletions of 11q22.3-q25 are
associated with atypical lung carcinoids and poor clinical outcome.
Am J Pathol. 179:1129–1137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matkar S, Thiel A and Hua X: Menin: A
scaffold protein that controls gene expression and cell signaling.
Trends Biochem Sci. 38:394–402. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Corbo V, Dalai I, Scardoni M, van Suylen
RJ, Dingemans AM, de Herder WW, de Krijger RR, Smit EF, Thunnissen
FB, Seldenrijk CA, et al: Men1 in pancreatic endocrine tumors:
Analysis of gene and protein status in 169 sporadic neoplasms
reveals alterations in the vast majority of cases. Endocr Relat
Cancer. 17:771–783. 2010. View Article : Google Scholar : PubMed/NCBI
|
